PUBLICATIONS
Curated Publications
Zwicker JI, Schlechter BL, Stopa JD, et al.
Targeting protein disulfide isomerase (PDI) with our isoquercetin therapy to improve hypercoagulability in advanced cancer.
Wang TF, Zwicker JI, Ay C, et al.
The use of direct oral anticoagulants (DOACs) for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH.
Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI.
Protein disulfide isomerase (PDI) inhibition blocks thrombin generation in humans by interfering with platelet factor V activation.
Abu Saadeh F, Norris L, O’Toole S, Gleeson N.
Venous thromboembolism (VTE) in ovarian cancer: incidence, risk factors and impact on survival.
Ay C, Simanek R, Vormittag R, et al.
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Vienna Cancer and Thrombosis Study (CATS).
Maria A. Lizarralde-Iragorri, Bindu Parachalil Gopalan, et al.
Isoquercetin for thromboinflammation in Sickle Cell Disease.
Muntjeeb M Syed, Pooja J Doshi, et al.
Isoquercitrin as an anti sickling agent: a multi-spectroscopic, thermophoresis and molecular modeling approach.
Yi L, et al.
Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells.
Lili Chen et al.
Binding interaction of quercetin-3-b-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal salient pharmacophore features.
